NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

Browse:
anti-PTK7/Auristatin-0101 antibody-drug conjugate PF-06647020
An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against human inactive tyrosine-protein kinase 7 (PTK7) linked, via a cleavable valine-citrulline linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101, with potential antineoplastic activity. Upon administration, anti-PTK7/Auristatin-0101 ADC PF-06647020 targets and binds to PTK7 expressed on tumor cells. Upon binding, internalization and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of PTK7-expressing tumor cells. PTK7, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:ADC PF-06647020
ADC PF-7020
anti-inactive tyrosine-protein kinase 7-ADC PF-06647020
anti-PTK7/vc-0101 ADC PF-06647020
Code name:h6M24-vc0101
PF 06647020
PF 7020
PF06647020